



Patient Ref. No. 251000000168320



CLIENT CODE : C000049066

Cert. No. MC-5333

CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,
Tonk Road
JAIPUR, 302015
Rajasthan, INDIAJAIPUR 302017
RAJASTHAN INDIA
9314660100

PATIENT NAME : KHEMCHAND SHARMA

PATIENT ID : KHEMM191290251

ACCESSION NO : 0251VL001659 AGE : 32 Years SEX : Male

ABHA NO :

DRAWN : 19/12/2022 09:32:00

RECEIVED : 19/12/2022 11:20:34

REPORTED : 19/12/2022 19:56:41

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212190004

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE**BLOOD COUNTS, EDTA WHOLE BLOOD**

HEMOGLOBIN (HB)	13.1	13.0 - 17.0	g/dL
METHOD : CYANIDE FREE DETERMINATION			
RED BLOOD CELL (RBC) COUNT	4.50	4.5 - 5.5	mil/ μ L
METHOD : ELECTRICAL IMPEDANCE			
WHITE BLOOD CELL (WBC) COUNT	10.40	High 4.0 - 10.0	thou/ μ L
METHOD : ELECTRICAL IMPEDANCE			
PLATELET COUNT	197	150 - 410	thou/ μ L
METHOD : ELECTRONIC IMPEDANCE			

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	39.6	Low 40 - 50	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	88.0	83 - 101	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.1	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	33.0	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	13.8	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER			
MENTZER INDEX	19.6		
MEAN PLATELET VOLUME (MPV)	11.3	High 6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			

WBC DIFFERENTIAL COUNT

NEUTROPHILS	63	40 - 80	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
LYMPHOCYTES	30	20 - 40	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
MONOCYTES	06	2 - 10	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
EOSINOPHILS	01	1 - 6	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
BASOPHILS	00	0 - 2	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168320



CLIENT CODE : C000049066

Cert. No. MC-5333

CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,
Tonk Road
JAIPUR, 302015
Rajasthan, INDIAJAIPUR 302017
RAJASTHAN INDIA
9314660100

PATIENT NAME : KHEMCHAND SHARMA

PATIENT ID : KHEMM191290251

ACCESSION NO : 0251VL001659 AGE : 32 Years SEX : Male

ABHA NO :

DRAWN : 19/12/2022 09:32:00

RECEIVED : 19/12/2022 11:20:34

REPORTED : 19/12/2022 19:56:41

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212190004

Test Report Status	Final	Results	Biological Reference Interval	Units
ABSOLUTE NEUTROPHIL COUNT		6.55	2.0 - 7.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		3.12	High 1.0 - 3.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.62	0.2 - 1.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.10	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0	Low 0.02 - 0.10	thou/ μ L
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		2.1		
* ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD				
E.S.R		02	0 - 14	mm at 1 hr
METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"				
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR)		98	74 - 99	mg/dL
METHOD : GLUCOSE OXIDASE				
GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD				
HBA1C		5.9	High Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)				
ESTIMATED AVERAGE GLUCOSE (EAG)		122.6	High < 116.0	mg/dL
METHOD : CALCULATED PARAMETER				
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS (POST PRANDIAL BLOOD SUGAR)		117	70 - 140	mg/dL
METHOD : GLUCOSE OXIDASE				
LIPID PROFILE, SERUM				
CHOLESTEROL, TOTAL		233	High < 200 Desirable 200 - 239 Borderline High > / = 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE				



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168320



CLIENT CODE : C000049066

Cert. No. MC-5333

CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,
Tonk Road
JAIPUR, 302015
Rajasthan, INDIAJAIPUR 302017
RAJASTHAN INDIA
9314660100

PATIENT NAME : KHEMCHAND SHARMA

PATIENT ID : KHEMM191290251

ACCESSION NO : 0251VL001659 AGE : 32 Years SEX : Male

ABHA NO :

DRAWN : 19/12/2022 09:32:00

RECEIVED : 19/12/2022 11:20:34

REPORTED : 19/12/2022 19:56:41

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212190004

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

TRIGLYCERIDES	72		< 150 Normal 150 - 199 Borderline High 200 - 499 High >=500 Very High	mg/dL
---------------	----	--	--	-------

METHOD : LIPASE/GPO-PAP NO CORRECTION

HDL CHOLESTEROL	69	High	< 40 Low >=60 High	mg/dL
-----------------	----	------	-----------------------	-------

METHOD : DIRECT CLEARANCE METHOD

CHOLESTEROL LDL	150	High	< 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >= 190 Very High	mg/dL
-----------------	-----	------	---	-------

NON HDL CHOLESTEROL	164	High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
---------------------	-----	------	--	-------

METHOD : CALCULATED PARAMETER

CHOL/HDL RATIO	3.4		3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
----------------	-----	--	--	--

LDL/HDL RATIO	2.2		0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	
---------------	-----	--	--	--

VERY LOW DENSITY LIPOPROTEIN	14.4		<= 30.0	mg/dL
------------------------------	------	--	---------	-------

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.28		0 - 1	mg/dL
------------------	------	--	-------	-------

METHOD : DIAZO WITH SULPHANILIC ACID

BILIRUBIN, DIRECT	0.07		0.00 - 0.25	mg/dL
-------------------	------	--	-------------	-------

METHOD : DIAZO WITH SULPHANILIC ACID

BILIRUBIN, INDIRECT	0.21		0.1 - 1.0	mg/dL
---------------------	------	--	-----------	-------

METHOD : CALCULATED PARAMETER

TOTAL PROTEIN	6.8		6.4 - 8.2	g/dL
---------------	-----	--	-----------	------

METHOD : BIURET REACTION, END POINT



Scan to View Details



Scan to View Report



Patient Ref. No. 25100000168320



CLIENT CODE : C000049066

Cert. No. MC-5333

CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,
Tonk Road
JAIPUR, 302015
Rajasthan, INDIAJAIPUR 302017
RAJASTHAN INDIA
9314660100

PATIENT NAME : KHEMCHAND SHARMA

PATIENT ID : KHEMM191290251

ACCESSION NO : 0251VL001659 AGE : 32 Years SEX : Male

ABHA NO :

DRAWN : 19/12/2022 09:32:00

RECEIVED : 19/12/2022 11:20:34

REPORTED : 19/12/2022 19:56:41

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212190004

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

ALBUMIN	4.1	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN	2.7	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.5	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	29	0 - 37	U/L
METHOD : TRIS BUFFER NO P5P IFCC / SFBC 37° C			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	65	High 0 - 40	U/L
METHOD : TRIS BUFFER NO P5P IFCC / SFBC 37° C			
ALKALINE PHOSPHATASE	46	39 - 117	U/L
METHOD : AMP OPTIMISED TO IFCC 37° C			
GAMMA GLUTAMYL TRANSFERASE (GGT)	44	11 - 50	U/L
METHOD : GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC) 37° C			
LACTATE DEHYDROGENASE	323	230 - 460	U/L
METHOD : GERMAN METHODS 37° C			
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	12	5.0 - 18.0	mg/dL
METHOD : UREASE KINETIC			
CREATININE, SERUM			
CREATININE	1.14	0.8 - 1.3	mg/dL
METHOD : ALKALINE PICRATE NO DEPROTEINIZATION			
BUN/CREAT RATIO			
BUN/CREAT RATIO	10.53		
METHOD : CALCULATED PARAMETER			
URIC ACID, SERUM			
URIC ACID	4.8	3.4 - 7.0	mg/dL
METHOD : URICASE PEROXIDASE WITH ASCORBATE OXIDASE			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	6.8	6.4 - 8.3	g/dL
METHOD : BIURET REACTION, END POINT			
ALBUMIN, SERUM			
ALBUMIN	4.1	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN			



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168320



CLIENT CODE : C000049066

Cert. No. MC-5333

CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,
Tonk Road
JAIPUR, 302015
Rajasthan, INDIAJAIPUR 302017
RAJASTHAN INDIA
9314660100

PATIENT NAME : KHEMCHAND SHARMA

PATIENT ID : KHEMM191290251

ACCESSION NO : 0251VL001659 AGE : 32 Years SEX : Male

ABHA NO :

DRAWN : 19/12/2022 09:32:00

RECEIVED : 19/12/2022 11:20:34

REPORTED : 19/12/2022 19:56:41

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212190004

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

GLOBULIN	2.7	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	139.6	137 - 145	mmol/L
METHOD : ION-SELECTIVE ELECTRODE			
POTASSIUM, SERUM	4.05	3.6 - 5.0	mmol/L
METHOD : ION-SELECTIVE ELECTRODE			
CHLORIDE, SERUM	102.0	98 - 107	mmol/L
METHOD : ION-SELECTIVE ELECTRODE			

Interpretation(s)**PHYSICAL EXAMINATION, URINE**

COLOR PALE YELLOW

METHOD : GROSS EXAMINATION

APPEARANCE SLIGHTLY HAZY

METHOD : GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

PH 5.5 4.7 - 7.5

METHOD : DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY 1.020 1.003 - 1.035

METHOD : IONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NOT DETECTED

METHOD : PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE NOT DETECTED NOT DETECTED

METHOD : GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

METHOD : SODIUM NITROPRUSSIDE REACTION

BLOOD NOT DETECTED NOT DETECTED

METHOD : PEROXIDASE ANTI PEROXIDASE

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD : DIPSTICK

UROBILINOGEN NORMAL NORMAL

METHOD : EHRlich REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD : NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168320



CLIENT CODE : C000049066

Cert. No. MC-5333

CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,
Tonk Road
JAIPUR, 302015
Rajasthan, INDIAJAIPUR 302017
RAJASTHAN INDIA
9314660100

PATIENT NAME : KHEMCHAND SHARMA

PATIENT ID : KHEMM191290251

ACCESSION NO : 0251VL001659 AGE : 32 Years SEX : Male

ABHA NO :

DRAWN : 19/12/2022 09:32:00

RECEIVED : 19/12/2022 11:20:34

REPORTED : 19/12/2022 19:56:41

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212190004

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	2-3	0-5	/HPF
METHOD : DIPSTICK, MICROSCOPY			
EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	

Interpretation(s)

THYROID PANEL, SERUM

T3	82.1	60.0 - 181.0	ng/dL
METHOD : CHEMILUMINESCENCE			
T4	5.60	4.5 - 10.9	µg/dL
METHOD : CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	1,486	0,550 - 4,780	µIU/mL
METHOD : CHEMILUMINESCENCE			

Interpretation(s)

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED
METHOD : GROSS EXAMINATION

* ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE A
METHOD : TUBE AGGLUTINATION
RH TYPE POSITIVE
METHOD : TUBE AGGLUTINATION

Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168320



CLIENT CODE : C000049066

Cert. No. MC-5333

CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)
AAKRITI LABS PVT LTD. A-430, AGRASEN MARGSRL Ltd
C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,
Tonk Road
JAIPUR, 302015
Rajasthan, INDIAJAIPUR 302017
RAJASTHAN INDIA
9314660100

PATIENT NAME : KHEMCHAND SHARMA

PATIENT ID : KHEMM191290251

ACCESSION NO : 0251VL001659 AGE : 32 Years SEX : Male ABHA NO :

DRAWN : 19/12/2022 09:32:00 RECEIVED : 19/12/2022 11:20:34 REPORTED : 19/12/2022 19:56:41

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212190004

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis,(Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals, AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g., galactosemia), Drugs- insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE:

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycaemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to :

I. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin).



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168320



CLIENT CODE : C000049066

Cert. No. MC-5333

CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd
C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,
Tonk Road
JAIPUR, 302015
Rajasthan, INDIA

JAIPUR 302017
RAJASTHAN INDIA
9314660100

PATIENT NAME : KHEMCHAND SHARMA

PATIENT ID : KHEMM191290251

ACCESSION NO : 0251VL001659 **AGE :** 32 Years **SEX :** Male **ABHA NO :**

DRAWN : 19/12/2022 09:32:00 **RECEIVED :** 19/12/2022 11:20:34 **REPORTED :** 19/12/2022 19:56:41

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212190004

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV. Interference of hemoglobinopathies in HbA1c estimation is seen in
a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c. HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels result from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

BLOOD UREA NITROGEN (BUN), SERUM- Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM- Higher than normal level may be due to:

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy

URIC ACID, SERUM- Causes of Increased levels:- Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels:- Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM- Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168320



CLIENT CODE : C000049066

Cert. No. MC-5333

CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)
AAKRITI LABS PVT LTD. A-430, AGRASEN MARGSRL Ltd
C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,
Tonk Road
JAIPUR, 302015
Rajasthan, INDIAJAIPUR 302017
RAJASTHAN INDIA
9314660100

PATIENT NAME : KHEMCHAND SHARMA

PATIENT ID : KHEMM191290251

ACCESSION NO : 0251VL001659 AGE : 32 Years SEX : Male

ABHA NO :

DRAWN : 19/12/2022 09:32:00

RECEIVED : 19/12/2022 11:20:34

REPORTED : 19/12/2022 19:56:41

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212190004

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

****End Of Report****

Please visit www.srlworld.com for related Test Information for this accession
TEST MARKED WITH '*' ARE OUTSIDE THE NABL ACCREDITED SCOPE OF THE LABORATORY.

Dr. Akansha Jain
Consultant Pathologist

Dr. Abhishek Sharma
Consultant Microbiologist


Scan to View Details



Scan to View Report

Date: 19/12/2022

BP: 140/90 mmHg BLC On Noch On HF 0.05 Hz LF 100 Hz



Handwritten signature and initials.

DR. NITIZ GOYAL
M.B.B.S., M.D.
RMC - 023319



Dr. KHEMCHAND SHARMA / 33 Yrs / M / 0 Cms / 0 Kg
 Date: 19 / 12 / 2022 Technician : VIJENDRA KUMAR Examined By:

Stage	Time	Duration	Speed(mph)	Elevation	METS	Rate	% THR	BP	RPP	PVC	Comments
Supine	00:10	0:10	01.1	00.0	01.0	074	40 %	140/90	103	00	
Standing	00:54	0:44	00.0	00.0	01.0	079	42 %	140/90	110	00	
HV	00:57	0:03	00.0	00.0	01.0	079	42 %	140/90	110	00	
Warm Up	01:01	0:04	01.0	00.0	01.0	086	46 %	140/90	120	00	
EXStart	01:06	0:05	01.7	10.0	01.1	092	49 %	140/90	128	00	
BRUCE Stage 1	04:06	3:00	01.7	10.0	04.7	126	67 %	140/90	176	00	
BRUCE Stage 2	07:06	3:00	02.5	12.0	07.1	153	82 %	140/90	214	00	
PeakEx	07:42	0:36	03.4	14.0	07.7	166	89 %	140/90	232	00	
Recovery	08:42	1:00	00.0	00.0	01.2	152	81 %	140/90	212	00	
Recovery	09:42	2:00	00.0	00.0	01.0	110	59 %	150/90	165	00	
Recovery	10:44	3:02	00.0	00.0	01.0	105	56 %	130/80	136	00	

REPORT :

FINAL IMPRESSION - TEST IS NEGATIVE FOR INDUCIBLE ISCHAEMIA

Dr. NITIZ GOYAL
 M.B.B.S., M.D.
 RMO - 023319
 Doctor : DR. NITIZ GOYAL



Name : **Mr. KHEMCHAD SHARMA**
Age/Gender: 32 Y/Male
Patient ID : 012212190004
BarcodeNo : 10070991
Referred By : Self

Registration No: 48584
Registered : 19/Dec/2022 09:32AM
Analysed : 19/Dec/2022 10:55AM
Reported : 19/Dec/2022 10:55AM
Panel : Medi Wheel (ArcoFemi
Healthcare Ltd)

DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

*** End Of Report ***

Page 1 of



Dr. Neera Mehta
M.B.B.S.,D.M.R.D.

RMCNO.005807/14853





Name : **Mr. KHEMCHAD SHARMA**

Registration No: 48584

Age/Gender: 32 Y/Male

Registered : 19/Dec/2022 09:32AM

Patient ID : 012212190004

Analysed : 19/Dec/2022 12:01PM

BarcodeNo : 10070991

Reported : 19/Dec/2022 12:02PM

Referred By : Self

Panel : Medi Wheel (ArcoFemi
Healthcare Ltd)

USG: WHOLE ABDOMEN (Male)

- LIVER** : Is normal in size, shape and echogenecity.
The IHBR and hepatic radicals are not dilated.
No evidence of focal echopoor/echorich lesion seen.
Portal vein diameter and common bile duct appear normal.
- GALL BLADDER** : Is normal in size, shape and echotexture. Walls are smooth and regular with normal thickness. There is no evidence of cholelithiasis.
- PANCREAS** : Is normal in size, shape and echotexture. Pancreatic duct is not dilated.
- SPLEEN** : Is normal in size, shape and echogenecity. Splenic hilum is not dilated.
- KIDNEYS** : Right Kidney:-Size: 102 x 48 mm, Left Kidney:-Size: 101 x 49 mm.
Bilateral Kidneys are normal in size, shape and echotexture,
corticomedullary differentiation is fair and ratio appears normal.
Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.
- URINARY BLADDER** : Bladder walls are smooth, regular and normal thickness.
No evidence of mass or stone in bladder lumen.
- PROSTATE**: Is normal in size, shape and echotexture,
measures: 34 x 32 x 31 mm, wt: 18 gms.
Its capsule is intact and no evidence of focal lesion.
- SPECIFIC** : No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.
No evidence of lymphadenopathy or mass lesion in retroperitoneum.
Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION :- NORMAL STUDY.

*** End Of Report ***

Page 1 of 1



Dr. Neera Mehta
M.B.B.S., D.M.R.D.

RMCNO.005807/14853